Analyses supporting the use of digitalis glycosides in patients with heart failure were presented in a Late-Breaking Science session today at Heart Failure 2026, the annual congress of the Heart Failure Association of the European Society of Cardiology.

Rare neuromuscular diseases often lack treatments because developing targeted drugs is slow, costly and risky for companies. A new approach using AI and stem cell models could finally shift the balance.

Broadly neutralizing antibodies (bNAbs) are among the most promising new treatments for HIV, offering the potential to forego traditional daily doses of antiretroviral drugs. In one recent clinical study of bNAbs identified and developed into therapies at Rockefeller University, participants who received a single dose of two bNAbs maintained a nearly undetectable viral load for up to 20 weeks, and a third did so for about a year. These outcomes suggest a potential future of treatment-free, long-term control of the virus.

Up to half of all women will experience some degree of pelvic organ prolapse in their lifetime. The condition can cause incontinence, constipation, and the descent of the bladder or uterus into the vagina. It can become debilitating from severe pressure and chronic pain.

A new editorial appearing in Osteoporosis International, titled “Beyond the fracture: coordinated action for bone health equity in Africa,” sets out a roadmap to address osteoporosis and fragility fractures across the continent. The paper is authored by members of the International Osteoporosis Foundation (IOF) Board of Governance from the African region.